PureTech Health Plc Forward P/E
What is the Forward P/E of PureTech Health Plc?
The Forward P/E of PureTech Health Plc is -505.47
What is the definition of Forward P/E?
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Forward P/E of companies in the Health Care sector on LSE compared to PureTech Health Plc
What does PureTech Health Plc do?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Companies with forward p/e similar to PureTech Health Plc
- Regis has Forward P/E of -2,236.00
- Freshpet Inc has Forward P/E of -1,232.16
- Hutchison China MediTech has Forward P/E of -995.34
- LXP Industrial Trust has Forward P/E of -987.00
- Cronos has Forward P/E of -807.00
- Sterling Plc has Forward P/E of -752.00
- PureTech Health Plc has Forward P/E of -505.47
- Kite Realty Trust has Forward P/E of -475.31
- Applied Optoelectronics Inc has Forward P/E of -446.00
- Cedar Realty Trust Inc has Forward P/E of -414.29
- Sunrun Inc has Forward P/E of -401.12
- ITM Power Plc has Forward P/E of -325.71
- Trilogiq SA has Forward P/E of -324.00